The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10434 malaria professionals are enjoying the free benefits of MalariaWorld today

antimalarial drugs

NOT Open Access | Malaria Parasite Clearance: What Are We Really Measuring

May 7, 2020 - 13:30 -- NOT Open Access
Khoury DS, Zaloumis SG, Grigg MJ, Haque A, Davenport MP; Interdisciplinary Approaches to Malaria Consortium
Trends Parasitol. 2020 May;36(5):413-426

Antimalarial drugs are vital for treating malaria and controlling transmission. Measuring drug efficacy in the field requires large clinical trials and thus we have identified proxy measures of drug efficacy such as the parasite clearance curve.

Antimalarial drugs impact chemical messenger secretion by blood platelets

May 4, 2020 - 14:01 -- Open Access
Xiong-Hang K, He J, Kemnetz-Ness K, Haynes C
Biochem Biophys Rep. 2020 Apr 22;22:100758

Advances in antimalarial drug development are important for combating malaria. Among the currently identified antimalarial drugs, it is suggested that some interact directly with the malarial parasites while others interact indirectly with the parasites. While this approach leads to parasite elimination, little is known about how these antimalarial drugs impact immune cells that are also critical in malarial response.

NOT Open Access | A chemically stable fluorescent mimic of dihydroartemisinin, artemether and arteether with conserved bioactivity and specificity shows high pharmacological relevance to the antimalarial drugs

April 13, 2020 - 14:01 -- NOT Open Access
Sissoko A, Vasquez-Ocmin P, Duval RA, et al.
ACS Infect Dis. 2020 Apr 8

Three novel tracers designed as fluorescent surrogates of artemisinin-derived antimalarial drugs (i. e., dihydroartemisinin, artemether, arteether and artemisone) were synthesized from dihydroartemisinin.

Efficacy of antimalarial drugs for treatment of uncomplicated falciparum malaria in Asian region: A network meta-analysis

December 23, 2019 - 16:09 -- Open Access
Naing C, Whittaker MA, Htet NH, Aye SN, Mak JW
PLoS ONE 14(12): e0225882

The WHO recommends artemisinin-based combination therapies (ACTs) for the treatment of uncomplicated falciparum malaria. Hence, monitoring the efficacy of antimalarial drugs is a key component of malaria control and elimination. The published randomized trials that assessed comparisons of ACTs for treating uncomplicated falciparum malaria reported conflicting results in treatment efficacy. A network meta-analysis is an extension of pairwise meta-analysis that can synthesize evidence simultaneously from both direct and indirect treatment comparisons. The objective was to synthesize evidence on the comparative efficacy of antimalarial drugs for treatment of uncomplicated falciparum malaria in Asian region.

Mode of action of quinoline antimalarial drugs in red blood cells infected by Plasmodium falciparum revealed in vivo

November 18, 2019 - 16:15 -- Open Access
Sergey Kapishnikov, Trine Staalsø, Yang Yang, Jiwoong Lee, Ana J. Pérez-Berná, Eva Pereiro, Yang Yang, Stephan Werner, Peter Guttmann, Leslie Leiserowitz, and Jens Als-Nielsen
PNAS November 12, 2019 116 (46) 22946-22952

The most widely used antimalarial drugs belong to the quinoline family. Their mode of action has not been characterized at the molecular level in vivo. We report the in vivo mode of action of a bromo analog of the drug chloroquine in rapidly frozen Plasmodium falciparum-infected red blood cells.

Medical Condition: 

NOT Open Access | Consequences of restricting antimalarial drugs to rapid diagnostic test‐positive febrile children in south‐west Nigeria

November 18, 2019 - 16:12 -- NOT Open Access
Catherine Olufunke Falade, Adebola Emanuel Orimadegun, Daniel Chandramohan, et al.
Tropical Medicine International Health, Volume24, Issue 11 November 2019 : 1291-1300

To investigate the consequence of restricting antimalarial treatment to febrile children that test positive to a malaria rapid diagnostic test (MRDT) only in an area of intense malaria transmission.

NOT Open Access | Changing Antimalarial Drug Sensitivities in Uganda

November 25, 2017 - 14:50 -- NOT Open Access
Stephanie A. Rasmussen, Frida G. Ceja, Roland A. Cooper, et al.
Antimicrob. Agents Chemother. December 2017 vol. 61 no. 12 e01516-17

Dihydroartemisinin-piperaquine (DP) has demonstrated excellent efficacy for the treatment and prevention of malaria in Uganda.


NOT Open Access | Adaptation and optimization of a fluorescence-based assay for in vivo antimalarial drug screening

June 27, 2017 - 18:05 -- NOT Open Access
Maria H. Arias, Eric Deharo, Alexis Valentin & Giovanny Garavito
Parasitology Research, July 2017, Volume 116, Issue 7, pp 1955–1962

The in vivo efficacy of potential antimalarials is usually evaluated by direct microscopic determination of the parasitaemia of Plasmodium-infected mice on Giemsa-stained blood smears.

Exploring the role of socioeconomic factors in the development and spread of anti-malarial drug resistance: a qualitative study

May 23, 2017 - 18:14 -- Open Access
Philip Emeka Anyanwu, John Fulton, Etta Evans and Timothy Paget
Malaria Journal 2017 16:203, 18 May 2017

Social and economic contexts can influence behaviours as they contribute in shaping norms and in creating opportunities that promote certain behaviours.

Substrate-analogous inhibitors exert antimalarial action by targeting the Plasmodium lactate transporter PfFNT at nanomolar scale

February 22, 2017 - 14:49 -- Open Access
André Golldack, Björn Henke, Bärbel Bergmann, Marie Wiechert, Holger Erler, Alexandra Blancke Soares, Tobias Spielmann, Eric Beitz
PLoS Pathog 13(2): e1006172

Resistance against all available antimalarial drugs calls for novel compounds that hit unexploited targets in the parasite.


Subscribe to RSS - antimalarial drugs